CRIS Current Research Information System

GRAMANTIERI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.915
NA - Nord America 3.483
EU - Europa 2.608
AF - Africa 220
SA - Sud America 182
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 2
Totale 10.426
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.431
SG - Singapore 1.109
CN - Cina 1.048
VN - Vietnam 843
IT - Italia 704
GB - Regno Unito 414
DE - Germania 276
HK - Hong Kong 257
SE - Svezia 255
FR - Francia 191
IN - India 161
NL - Olanda 155
KR - Corea 128
BR - Brasile 124
RU - Federazione Russa 116
IE - Irlanda 98
JP - Giappone 93
CH - Svizzera 81
FI - Finlandia 77
ZA - Sudafrica 68
UA - Ucraina 61
BG - Bulgaria 41
CI - Costa d'Avorio 41
ID - Indonesia 41
TG - Togo 40
TH - Thailandia 36
SC - Seychelles 32
CA - Canada 31
EE - Estonia 28
PH - Filippine 28
BD - Bangladesh 23
JO - Giordania 23
EC - Ecuador 21
PK - Pakistan 21
PL - Polonia 18
MX - Messico 17
AT - Austria 16
IQ - Iraq 16
TW - Taiwan 16
EU - Europa 15
AR - Argentina 14
TR - Turchia 14
DZ - Algeria 13
BE - Belgio 12
HR - Croazia 10
MK - Macedonia 9
ES - Italia 8
LT - Lituania 8
UZ - Uzbekistan 8
MY - Malesia 7
PE - Perù 7
RO - Romania 7
NG - Nigeria 6
SA - Arabia Saudita 6
CL - Cile 5
CZ - Repubblica Ceca 5
GR - Grecia 5
IL - Israele 5
LB - Libano 5
AM - Armenia 4
EG - Egitto 4
PY - Paraguay 4
AZ - Azerbaigian 3
CO - Colombia 3
IR - Iran 3
KZ - Kazakistan 3
MA - Marocco 3
NP - Nepal 3
TN - Tunisia 3
AE - Emirati Arabi Uniti 2
DK - Danimarca 2
ET - Etiopia 2
GH - Ghana 2
HU - Ungheria 2
MD - Moldavia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SR - Suriname 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
CR - Costa Rica 1
CU - Cuba 1
GE - Georgia 1
HN - Honduras 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ML - Mali 1
MM - Myanmar 1
MR - Mauritania 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
Totale 10.422
Salva come PNG Salva come JPEG
Città #
Singapore 786
Ashburn 445
Southend 349
Fairfield 302
Hefei 272
Bologna 245
Hong Kong 235
Chandler 214
Ho Chi Minh City 205
San Jose 205
Hanoi 196
Woodbridge 159
Santa Clara 156
Houston 148
Wilmington 131
Seattle 129
Seoul 118
Beijing 117
Boardman 100
Dublin 98
Princeton 88
Council Bluffs 86
Lauterbourg 80
Ann Arbor 79
Cambridge 79
Dallas 76
Bern 75
Tokyo 75
Los Angeles 68
Helsinki 61
Da Nang 48
Milan 47
New York 44
Abidjan 41
Sofia 41
Lomé 40
Dong Ket 35
Jacksonville 34
Westminster 34
Amsterdam 33
Johannesburg 32
Nanjing 32
Padova 32
Buffalo 29
Redondo Beach 28
Haiphong 26
Munich 25
Bengaluru 24
Berlin 24
Florence 24
Amman 23
Frankfurt am Main 22
Jakarta 22
Chicago 20
Jinan 19
Saint Petersburg 19
San Diego 19
São Paulo 19
Zhengzhou 18
Guangzhou 17
Hebei 17
Turin 17
Bangkok 15
Düsseldorf 14
Shanghai 14
Nuremberg 13
Orem 13
Hải Dương 12
Lahore 12
Montreal 12
Nanchang 12
Brussels 11
Des Moines 11
Rome 11
Shenzhen 11
Tianjin 11
Brooklyn 10
Jiaxing 10
London 10
Phoenix 10
Pune 10
Quito 10
Shenyang 10
Vienna 10
Warsaw 10
Bremen 9
Changsha 9
Chennai 9
Hangzhou 9
Medford 9
Norwalk 9
Parma 9
Tongling 9
Toronto 9
Verona 9
Bühl 8
Can Tho 8
Dearborn 8
Falls Church 8
Forlì 8
Totale 6.674
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 277
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 257
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 230
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 226
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 223
LncRNAs as novel players in hepatocellular carcinoma recurrence 221
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 211
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 211
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 211
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 203
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 200
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 191
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 185
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 185
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 180
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 176
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 174
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 172
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 172
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 170
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 169
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 166
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 164
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 164
TP53/MicroRNA interplay in hepatocellular carcinoma 164
Improving accuracy in the diagnosis of small HCC (< 20 mm) on cirrhosis by a combined CT-MRI Ultrasound navigation system. Preliminary report of a work in progress. 162
Oncogenic role of miR-483-3p at the IGF2/483 locus. 161
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 161
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 161
Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas 161
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 158
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 155
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 153
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 152
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. 149
MicroRNAs in Animal Models of HCC 149
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 147
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 147
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 144
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 143
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 141
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 138
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 135
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 134
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 134
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 133
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 129
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 127
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches 123
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 123
Characterization of small nucleolar RNA retaining transcripts in human normal and cancer cells 119
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 118
Efficacy of superselective TACE in treatment of HCC 117
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma 113
Notch3 intracellular domain accumulates in HepG2 cell line. 109
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 109
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 108
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 107
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 91
miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature 85
Emerging role of microRNAs in the treatment of hepatocellular carcinoma 81
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 77
null 77
Animal models of hepatocellular carcinoma prevention 75
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 70
Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver 69
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 66
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 59
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 58
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 57
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 54
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 53
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 51
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 51
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 45
MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma 36
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 36
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 34
Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy 27
Totale 10.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.906
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.906
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021169 0 0 0 0 0 0 0 0 0 47 24 98
2021/2022976 55 44 60 86 74 47 19 96 36 84 253 122
2022/20231.084 99 121 62 123 65 93 21 57 192 28 76 147
2023/2024411 32 70 19 37 55 79 13 20 19 30 13 24
2024/20251.731 87 222 141 116 214 55 121 45 44 181 133 372
2025/20264.522 421 427 400 322 455 327 526 243 1.094 307 0 0
Totale 10.674